会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 31. 发明公开
    • 인간 중간엽줄기세포의 분화 촉진용 조성물
    • 促进人类间质干细胞分化的组合物
    • KR1020120140450A
    • 2012-12-31
    • KR1020110060194
    • 2011-06-21
    • (주)아모레퍼시픽
    • 신동욱노민수박수남
    • A61K36/62C12N5/0775A61P17/00
    • A61K36/62A61Q90/00C12N5/0662C12N5/0669
    • PURPOSE: A composition with Nelumbinis Semen extracts as an active ingredient for promoting the differentiation of adipocyte in human mesenchymal stem cell is provided to promote differentiating the adipocyte from a human mesenchymal stem cell to produce lipid droplet, enhance the electricity and the volume of skin and reduce wrinkles. CONSTITUTION: A composition for skin external application for promoting the differentiation of adipocyte contains Nelumbinis Semen extracts as an active ingredient. The composition promotes differentiating adipocyte from a mesenchymal stem cell. The mesenchymal stem cell is a human mesenchymal cell. The composition increases adipocyte tissue. For the total weight of the composition, a Nelumbinis Semen extract weighs ranging from 0.001 to 30%. The composition enhances the volume of skin and the elasticity of skin, and reduces skin wrinkles. A pharmaceutical composition for promoting the differentiation of a adipocyte cell contains Nelumbinis Semen as an active ingredient. A Nelumbinis Semen extract is administered from 0.001mg /kg /day-2000mg /kg /day. [Reference numerals] (AA) Relative revelation amount; (BB) Negative control group; (CC) Ligustri Fructus; (DD) Veratri Rhizoma Et Radix; (EE) Forsythiae Fructus; (FF) Nelumbo semen
    • 目的:提供具有Nelumbinis Semen提取物作为促进人间充质干细胞中脂肪细胞分化的活性成分的组合物,以促进脂肪细胞与人间充质干细胞的分化,产生脂滴,增强皮肤的电力和体积, 减少皱纹。 构成:用于促进脂肪细胞分化的皮肤外用应用组合物含有Nelumbinis Semen提取物作为活性成分。 该组合物促进脂肪细胞与间充质干细胞分化。 间充质干细胞是人类间充质细胞。 组合物增加脂肪细胞组织。 对于组合物的总重量,Nelumbinis Semen提取物的重量范围为0.001至30%。 该组合物增强皮肤的体积和皮肤的弹性,并减少皮肤皱纹。 用于促进脂肪细胞分化的药物组合物含有Nelumbinis Semen作为活性成分。 Nelumbinis精液提取物以0.001mg / kg /天-2000mg / kg /天施用。 (附图标记)(AA)相对启示量; (BB)阴性对照组; (CC)Ligustri Fructus; (DD)Veratri Rhizoma Et Radix; (EE)连翘; (FF)Nelumbo精液
    • 37. 发明公开
    • 키메린을 함유하는 지방세포 분화 억제 및 지방세포 내의 지질체 수준 감소용 조성물
    • 用于抑制ADIPOCYTE中脂质体降解水平和降低水平的组合物
    • KR1020100025070A
    • 2010-03-09
    • KR1020080083683
    • 2008-08-27
    • (주)아모레퍼시픽
    • 최현노민수김한곤
    • A61K38/16A61P3/04
    • PURPOSE: A composition for suppressing differentiation and growth of adipocytes is provided to treat or prevent circulatory system disease or ischemic heart disease. CONSTITUTION: A composition for suppressing differentiation or growth of adipocytes contains 0.00001 to 15 weight% of chemerin. The adipocyte is human bone marrow mesenchymal stem cell. A pharmaceutical composition is used in the form of oral administration formulation or injection. The oral administration formulation is formulated in capsule, tablet, suspension, syrup or powder. A functional health food composition for preventing or treating diabetes, hyperlipidemia, hypercholesterolemia, circulatory system diseases contains 0.00001-10 weight% of chemerin. The health food is used in the form of caramel, chocolate, diet bar or snack. A cosmetic composition for treating obesity contains 0.00001-10 weight% of chemerin as an active ingredient. The cosmetic composition is used in the form of massage cream, body lotion, body cream, body oil, or body essence.
    • 目的:提供一种抑制脂肪细胞分化和生长的组合物,用于治疗或预防循环系统疾病或缺血性心脏病。 构成:用于抑制脂肪细胞分化或生长的组合物含有0.00001〜15重量%的凯美宾。 脂肪细胞是人骨髓间充质干细胞。 药物组合物以口服给药制剂或注射剂的形式使用。 口服给药制剂配制成胶囊,片剂,悬浮液,糖浆或粉剂。 用于预防或治疗糖尿病,高脂血症,高胆固醇血症,循环系统疾病的功能保健食品组合物含有0.00001-10重量%的凯美瑞。 保健食品以焦糖,巧克力,饮食酒吧或小吃的形式使用。 用于治疗肥胖的化妆品组合物含有0.00001-10重量%的作为活性成分的凯美瑞。 化妆品组合物以按摩霜,身体乳液,身体霜,身体油或身体精华的形式使用。
    • 39. 发明公开
    • 스핑고실포스포릴콜린의 작용을 조절하는 약학 조성물
    • 用于控制磷脂酰胆碱的功能的药物组合物
    • KR1020090056584A
    • 2009-06-03
    • KR1020070123798
    • 2007-11-30
    • (주)아모레퍼시픽재단법인서울대학교산학협력재단
    • 고재영한은실김혁김정주노민수김상희임채민
    • A61K31/16A61K31/13A61P31/00
    • A61K31/16
    • A pharmaceutical composition regulating the activity of sphingosylphosphorylcholine(SPC) is provided to regulate cell proliferation, inflammation and pruritus and treat inflammmatin or pruritus of dermatitis such as atopic dermatitis. A pharmaceutical composition which regulates the activity of sphingosylphosphorylcholine(SPC) comprises a compound of the chemical formula 1 or its pharmaceutically allowable salt. In the chemical formula 1, X is O or S, Y is CH2 or carbonyl. R1 is hydrogen or C1-10 alkyl, R2 is hydrogen or methyl, but when X is O, either R1 or R2 cannot be hydrogen, R3 is C1-4 alkyl. A method for manufacturing a compound of the chemical formula 1a comprises: a step of reacting a compound of the chemical formula 2 and a compound of the chemical formula 3 under the presence of base to obtain a compound of the chemical formula 4; a step of stirring the compound of the chemical formula 4 under the presence of base to obtain a compound of the chemical formula 5; and a step of performing the peptide bond between the compound of the chemical formula 5 and a compound of the chemical formula 6 to obtain the compound of the chemical formula 1a.
    • 提供调节肌动蛋白磷酰胆碱(SPC)活性的药物组合物,用于调节细胞增殖,炎症和瘙痒,并治疗诸如特应性皮炎等炎性炎症或皮炎瘙痒症。 调节鞘糖基磷酰胆碱(SPC)活性的药物组合物包含化学式1的化合物或其药学上可允许的盐。 在化学式1中,X为O或S,Y为CH 2或羰基。 R1是氢或C1-10烷基,R2是氢或甲基,但当X是O时,R1或R2不能是氢,R3是C1-4烷基。 制备化学式1a化合物的方法包括:使化学式2的化合物与化学式3化合物在碱存在下反应得到化学式4的化合物的步骤; 在碱的存在下搅拌化学式4的化合物以获得化学式5的化合物的步骤; 在化学式5的化合物与化学式6的化合物之间进行肽键的步骤,得到化学式1a的化合物。